We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
-14.6%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$68.5B
AUM Growth
-$9.16B
Cap. Flow
+$4.06B
Cap. Flow %
5.93%
Top 10 Hldgs %
21.45%
Holding
3,375
New
359
Increased
2,433
Reduced
285
Closed
282

Top Buys

Rank Stock Value
1
LIN icon
Linde
LIN
+$124M
2
AAPL icon
Apple
AAPL
+$110M
3
MSFT icon
Microsoft
MSFT
+$104M
4
AMZN icon
Amazon
AMZN
+$71.3M
5
WBD icon
Warner Bros
WBD
+$69.6M

Top Sells

Rank Stock Value
1
T icon
AT&T
T
+$61.6M
2
CERN
Cerner Corp
CERN
+$50.9M
3
NXPI icon
NXP Semiconductors
NXPI
+$31.4M
4
AZPN
ASPEN TECHNOLOGY INC
AZPN
+$30.4M
5
YUMC icon
Yum China
YUMC
+$16.3M

Sector Composition

Rank Sector Weight
1 Technology 23.13%
2 Healthcare 14.42%
3 Financials 13.45%
4 Consumer Discretionary 10.49%
5 Industrials 9.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SQZ
3301
DELISTED
SQZ Biotechnologies Company
SQZ
-25,148
Closed -$121K
USX
3302
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
-32,236
Closed -$125K
EVLO
3303
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
-1,441
Closed -$98K
ONCR
3304
DELISTED
Oncorus, Inc.
ONCR
-19,535
Closed -$35K
TCRR
3305
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
-35,135
Closed -$97K
SGTX
3306
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
-862
Closed -$16K
CDAK
3307
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
-13,218
Closed -$83K
SFT
3308
DELISTED
Shift Technologies, Inc. Class A Common Stock
SFT
-6,029
Closed -$133K
RUBY
3309
DELISTED
Rubius Therapeutics, Inc
RUBY
-46,907
Closed -$258K
ATNX
3310
DELISTED
Athenex, Inc. Common Stock
ATNX
-5,352
Closed -$89K
HYRE
3311
DELISTED
HyreCar Inc. Common Stock
HYRE
-13,507
Closed -$32K
IVC
3312
DELISTED
Invacare Corporation
IVC
-46,921
Closed -$66K
EAR
3313
DELISTED
Eargo, Inc. Common Stock
EAR
-1,409
Closed -$149K
OYST
3314
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
-13,531
Closed -$158K
DS
3315
DELISTED
Drive Shack Inc.
DS
-73,645
Closed -$113K
CLVS
3316
DELISTED
Clovis Oncology, Inc.
CLVS
-114,265
Closed -$231K
NH
3317
DELISTED
NantHealth, Inc
NH
-1,260
Closed -$14K
LOTZ
3318
DELISTED
CarLotz, Inc. Class A Common Stock
LOTZ
-63,157
Closed -$87K
AKUS
3319
DELISTED
Akouos Inc
AKUS
-26,649
Closed -$127K
QTNT
3320
DELISTED
Quotient Limited Ordinary Shares
QTNT
-1,792
Closed -$86K
ZY
3321
DELISTED
Zymergen Inc. Common Stock
ZY
-90,086
Closed -$260K
RMO
3322
DELISTED
Romeo Power, Inc.
RMO
-111,497
Closed -$166K
AMPE
3323
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
-548
Closed -$77K
HMTV
3324
DELISTED
Hemisphere Media Group, Inc.
HMTV
-21,558
Closed -$99K
NBEV
3325
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
-124,186
Closed -$72K

Similar funds

RhumbLine Advisers's Q2 2022 Portfolio in Review

As of Q2 2022, RhumbLine Advisers held 3,375 positions worth $68.5B, down 12% from $77.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

RhumbLine Advisers deployed $4.06B of net new capital in Q2 2022, opening 359 new positions and adding to 2,433 existing holdings. Its largest new stake was Aspen Technology Inc: 81,883 shares worth $15M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was AT&T, an estimated $61.6M trimmed.

  • RhumbLine Advisers's largest Q2 2022 buy was Aspen Technology Inc: 81,883 shares worth $15M.
  • RhumbLine Advisers added most to Linde in Q2 2022, an estimated $124M increase.
  • RhumbLine Advisers's biggest Q2 2022 reduction was AT&T, cutting an estimated $61.6M.
  • RhumbLine Advisers fully exited Cerner Corp in Q2 2022, selling an estimated $50.9M.
  • RhumbLine Advisers's ten largest holdings make up 21% of its $68.5B portfolio in Q2 2022.
  • RhumbLine Advisers opened 359 new positions and closed 282 in Q2 2022.
  • RhumbLine Advisers's portfolio value fell 12% quarter-over-quarter to $68.5B.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.